Status:
COMPLETED
Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome
Lead Sponsor:
Peking University People's Hospital
Conditions:
Advanced MDS Without Identical Sibling Donor
Eligibility:
All Genders
2-60 years
Brief Summary
Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS), especially for advanced MDS (blast \>5%). However, many patients ...
Eligibility Criteria
Inclusion
- Patients with MDS (1)intermediate-2 or high risk (2)low or intermediate-1 risk with drug resistance or disease progression
- without identical sibling donor
Exclusion
- Contraindication to HSCT
- Pregnancy
- Mental illness
Key Trial Info
Start Date :
April 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT01793675
Start Date
April 1 2003
End Date
December 1 2014
Last Update
April 29 2015
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital, Nanfang Medical University
Guangzhou, Guangdong, China, 510515
2
Hebei Tangshan Steel and Iron Company Hospital
Tangshan, Hebei, China
3
Nanjing Gulou Hospital
Nanjing, Jiangsu, China
4
Suzhou University The 1st Affiliated Hospital
Suzhou, Jiangsu, China